← All trials
NCT05652205
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2022
- Primary completion
- Jul 30, 2024
- Completion date
- Jul 30, 2024
- First posted
- Dec 15, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 100
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AbbVieLead sponsor
- AbbVieStudy director
- Ironwood PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.